...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Canadian Journal of Neurological Sciences: le Journal Canadien des Sciences Neurologiques >Level I Evidence Should not be Equated to Standard of Care for Brain Metastases
【24h】

Level I Evidence Should not be Equated to Standard of Care for Brain Metastases

机译：I级证据不应等同于脑转移的护理标准

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In this issue, O'Halloran et al.1 have written a comprehensive review of current and upcoming management options for brain metastases. The goal of this editorial is to provide a pragmatic neurosurgical perspective on this matter.We usher into an unprecedented era in oncology. Molecular diagnosis has led to a revolution in the management of malignancies that are most frequently responsible for the development of brain metastases, such as non-small cell lung cancer, melanoma, and breast cancer. Immune checkpoint inhibitors and target-specific tyrosine kinase inhibitors have been demonstrated to provide significant improvement in the overall survival of such patients. The proportion of patients who will develop and live for a prolonged period of time with brain metastases is expected to increase in the coming years. Consequently, therapies used to manage these tumors have to be safe and be able to be delivered quickly without disrupting the schedule of systemic therapy.
机译：在本期中，O'Halloran等人1对当前和即将到来的脑转移治疗方案进行了全面综述。这篇社论的目的是提供一个实用的神经外科视角来看待这个问题。我们迎来了一个前所未有的肿瘤学时代。分子诊断已经在恶性肿瘤的治疗方面引发了一场革命，而恶性肿瘤最常导致脑转移，如非小细胞肺癌、黑色素瘤和乳腺癌。免疫检查点抑制剂和靶向特异性酪氨酸激酶抑制剂已被证明能显著改善此类患者的总体生存率。在未来的几年里，患有脑转移瘤的患者的比例有望增加。因此，用于治疗这些肿瘤的疗法必须是安全的，并且能够在不中断系统治疗计划的情况下快速提供。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号